In light of our past findings on the suppressive effects of Nrf2 on AR expression in PCa cells[150], and the in vitro efficacy of Nrf2-activators like sulforaphane[70,220] and CDDO-me[71] in similarly suppressing AR and increasing the efficacy of antiandrogens (discussed later in this section), we believe that DMF, a relatively safe and well tolerated Nrf2 activator, should be tested as a suppressor of CRPC outgrowth in PCa patients undergoing ADT treatment. This evidence concerns the gene NFE2L2 and posterior cortical atrophy.